Henry H. Washington III was diagnosed with prostate cancer at 39 during a routine military physical, years before the age many men associate with screening. His case is not a general argument that every man should test early in the same way. It is a more specific warning: for Black men, men with a strong family history, and many veterans already in regular medical systems, waiting until symptoms appear or assuming screening starts at 55 can miss the period when earlier discussion matters most.
Why Washington’s diagnosis changes the usual screening conversation
Washington’s family history was severe. His father and grandfather both died of prostate cancer, and he was diagnosed decades before the standard age range often cited for routine screening discussions. That combination makes his survival story useful not because it is dramatic, but because it shows how risk level can shift the timeline.
For the general population, prostate-specific antigen screening is often discussed around ages 55 to 69. But that is not the right default for everyone. Black men face a higher burden: about 1 in 6 are expected to be diagnosed, they are 1.7 times more likely than white men to be diagnosed, and 2.1 times more likely to die from the disease. In that setting, an earlier conversation at 40 is not overreaction; it is risk-based screening.
The common misreading is that prostate cancer screening is only necessary after symptoms appear, or that age 55 applies equally to all men. Washington’s experience argues against both. Symptoms can come late, and men with family history or other high-risk features may need a personalized plan before 50.
Who should think about PSA testing earlier, and who may not need the same schedule?
PSA testing is a blood test, not a diagnosis by itself. It can help identify who may need closer follow-up, repeat testing, or further evaluation such as biopsy. That makes the first decision less about “Do I have cancer?” and more about “Am I in a group where earlier monitoring is reasonable?”
| Group | When to start the discussion | Why the timing differs | What to do next |
|---|---|---|---|
| Average-risk men | Often around 55 | General screening recommendations usually focus on ages 55 to 69 | Discuss benefits, limits, and whether PSA testing fits your situation |
| Black men | Around 40 | Higher diagnosis and death rates make delayed discussion less appropriate | Ask for a personalized screening schedule rather than waiting for symptoms |
| Men with a father, brother, or multiple close relatives with prostate cancer | Around 40 or before 50 | Family history raises the chance of earlier or more aggressive disease | Monitor PSA trends and review screening intervals with a clinician |
| Men with inherited gene mutations or other major risk factors | Earlier individualized discussion | Risk may be high enough that standard timing is not suitable | Use specialist guidance for testing frequency and follow-up thresholds |
Earlier discussion does not mean automatic biopsy or aggressive treatment. It means not using a one-size-fits-all age cutoff when the risk profile is clearly different. A practical checkpoint from the source material is simple: if you are Black, have a family history, or know you are high risk, do not wait until after 50 to ask about PSA monitoring.
What PSA can and cannot tell you
PSA screening can help catch a problem before symptoms develop, which is the main reason Washington pushes for earlier attention in high-risk men. But the test has limits. A PSA result cannot confirm prostate cancer on its own, and an elevated level can lead to repeat testing, imaging, or biopsy that may ultimately show no cancer.
That trade-off matters because screening is not just a yes-or-no issue. It is a sequence of decisions. A borderline or rising PSA may justify closer follow-up, while a single result without context may not. Men should know that the realistic benefit of screening is earlier detection in the right group, not certainty from one blood draw.
Symptoms still matter, but they are not a safe trigger for starting the conversation. Difficulty urinating, blood in urine or semen, or persistent bone pain should prompt medical evaluation rather than watchful waiting. Those are not signs to schedule a routine future check; they are reasons to seek care now.
The part men often avoid: treatment side effects and mental health
Washington also speaks openly about what happens after diagnosis, which is where many awareness campaigns become vague. Prostate cancer treatment can lead to urinary, bowel, and sexual dysfunction. Those effects can alter daily function, relationships, confidence, and self-esteem, even when treatment is medically successful.
That is especially relevant in communities where men may already avoid discussing intimate symptoms or emotional strain. Destigmatizing the conversation is not just about getting screened. It also affects whether men report side effects early, ask for rehabilitation or counseling, and stay engaged with follow-up care instead of withdrawing after treatment.
For men in treatment or remission, a useful stop signal is isolation. If side effects are affecting mood, relationships, or willingness to leave the house, that is a reason to involve a clinician, support group, or mental health professional rather than trying to absorb it alone.
How Washington turned a personal case into practical support in Atlanta
Washington’s advocacy did not stop at telling his story. Through the Henry H. Washington 3 Foundation in Atlanta, he has tied awareness to support that people can actually use: prostate cancer education, veteran support, access to specialist nurses, and youth mentoring. That combination reflects his own background as both a survivor and a veteran who understands how discipline and silence can coexist in men’s health.
The veteran angle matters because many veterans already have regular contact with healthcare systems but may still delay asking direct questions about prostate symptoms, PSA testing, or treatment side effects. Washington’s message is more concrete than “be proactive.” If your risk is elevated, ask for a personalized screening schedule before age 50, track PSA levels over time, and do not treat embarrassment as a reason to postpone care.
His story is most useful when read as a decision point, not a slogan. Men at higher risk, especially Black men and those with a family history, should move the conversation earlier. Men with symptoms should stop waiting. Men already in treatment should speak up when side effects start affecting function or mental health.
Quick questions
Does every man need PSA screening at 40?
No. The earlier starting point is most relevant for Black men, men with a family history, and others at high risk.
Should men wait for symptoms before getting checked?
No. Prostate cancer can be present before symptoms appear, which is why risk-based screening discussions matter.
If PSA is high, does that mean cancer is confirmed?
No. PSA can signal the need for further evaluation, but it does not diagnose cancer by itself.